NXTC NextCure
Price Chart
Executive Summary
NextCure announced initiation of dose optimization for its CDH6-directed ADC SIM0505 in platinum-resistant ovarian cancer, with FDA Fast Track designation. Phase 1 data will be presented at ASCO 2026, but no financial or efficacy data was released.
Actionable Insight
Monitor ASCO 2026 for Phase 1 data; no near-term catalyst. Clinical success is binary with high risk. Small cap with history of negative stock moves on prior neutral news.
Key Facts
- FDA granted Fast Track designation for SIM0505 in platinum-resistant ovarian cancer
- Dose optimization portion of Phase 1 study initiated in PROC patients
- Phase 1 data readout planned for ASCO 2026
- NextCure holds exclusive global rights for SIM0505 except China, Hong Kong, Macau, Taiwan
Financial Impact
No financial data disclosed; $34M market cap biotech with no approved products
Risk Factors
- Clinical trial failure or underwhelming efficacy/safety data
- Cash burn without revenue; potential need for dilutive financing
- High volatility typical for micro-cap biotech
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3286574 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
9d ago
|
8-K
| $3.38 $2.95 | ▼ −12.72% | ▼ −9.97% | $2.21 (−34.62%) |
|
Jun 1, 2026
9d ago
|
Press Release
| $3.38 $2.95 | ▼ −12.72% | ▼ −9.97% | $2.21 (−34.62%) |
|
May 7, 2026
4w ago
|
8-K
| $9.76 $10.25 | ▲ +5.02% | ▲ +3.56% | $2.21 (−77.36%) |
|
May 4, 2026
5w ago
|
Press Release
| $8.92 $9.78 | ▲ +9.64% | ▲ +6.71% | $2.21 (−75.22%) |
|
Apr 24, 2026
6w ago
|
DEFA14A
| $9.62 $8.92 | ▼ −7.28% | ▼ −7.68% | $2.21 (−77.03%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $10.97 $9.25 | ▼ −15.68% | ▼ −16.76% | $2.21 (−79.85%) |
|
Mar 5, 2026
13w ago
|
8-K
| $12.39 $12.68 | ▲ +2.34% | ▲ +3.87% | $2.21 (−82.16%) |
|
Mar 5, 2026
13w ago
|
Press Release
| $12.39 $12.68 | ▲ +2.34% | ▲ +3.87% | $2.21 (−82.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access